Patent ID: 6017897
Filing Date: 2000-01-25
Classification: A61K,C07K,C12N

Abstract:
An immunogenic composition for in vivo administration to a host for the generation in the host of a protective immune response to RSV F protein, comprising a plasmid vector comprising:a first nucleotide sequence selected from the group consisting of a nucleic acid sequence having SEQ ID No: 1, a nucleic acid sequence having SEQ ID No: 3, a nucleic acid sequence encoding an RSV F protein having SEQ ID No: 2, and a nucleic acid sequence encoding an RSV F protein fragment having SEO ID No: 4;a promoter sequence operatively coupled to the first nucleotide sequence for expression of said RSV F protein or said RSV F protein fragment in the host, anda second nucleotide sequence located between said first nucleotide sequence and said promoter sequence and comprising a pair of splice sites to prevent aberrant mRNA splicing and to enhance the immunoprotective ability of said RSV F protein or said RSV F protein fragment when expressed in vivo from said vector in a host; anda pharmaceutically-acceptable carrier therefor.